oxybutynin transdermal (Rx, OTC)

Brand and Other Names:Oxytrol, Oxytrol For Women
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

transdermal patch

  • 3.9mg/day

Overactive Bladder

Indicated for symptom relief in uninhibited neurogenic or reflex neurogenic bladder (urge incontinence, frequency and urgency)

Apply 1 patch (releases 3.9 mg/day) twice/week (ie, q3-4 days)

Rotate application sites; need not be removed during bathing, swimming, exercising, or sleeping

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and oxybutynin transdermal

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (3)

              • lonafarnib

                oxybutynin transdermal will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Closely monitor for arrhythmias and events (eg, syncope, heart palpitations) since lonafarnib effect on QT interval is unknown.

              • pramlintide

                pramlintide, oxybutynin transdermal. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility.

              • secretin

                oxybutynin transdermal decreases effects of secretin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Concomitant use of anticholinergic drugs may cause a hyporesponse to stimulation testing with secretin. Discontinue anticholinergic drugs at least 5 half-lives before administering secretin.

              Monitor Closely (107)

              • abobotulinumtoxinA

                abobotulinumtoxinA increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.

              • aclidinium

                oxybutynin transdermal and aclidinium both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • amantadine

                oxybutynin transdermal, amantadine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Potential for increased anticholinergic adverse effects.

              • amitriptyline

                oxybutynin transdermal and amitriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • amoxapine

                oxybutynin transdermal and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • anticholinergic/sedative combos

                anticholinergic/sedative combos and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • aripiprazole

                oxybutynin transdermal decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                oxybutynin transdermal decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.

                aripiprazole increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • atracurium

                atracurium and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • atropine

                atropine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • atropine IV/IM

                atropine IV/IM and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • avapritinib

                oxybutynin transdermal will increase the level or effect of avapritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              • axitinib

                oxybutynin transdermal increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              • belladonna alkaloids

                belladonna alkaloids and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • belladonna and opium

                belladonna and opium and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • benperidol

                oxybutynin transdermal decreases levels of benperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                oxybutynin transdermal decreases levels of benperidol by pharmacodynamic antagonism. Use Caution/Monitor.

                benperidol increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • benztropine

                benztropine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use.

              • bethanechol

                bethanechol increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • carbachol

                carbachol increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • cevimeline

                cevimeline increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • chlorpromazine

                oxybutynin transdermal decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                oxybutynin transdermal decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.

                chlorpromazine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • cisatracurium

                cisatracurium and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • clomipramine

                oxybutynin transdermal and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • clozapine

                oxybutynin transdermal decreases levels of clozapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                oxybutynin transdermal decreases levels of clozapine by pharmacodynamic antagonism. Use Caution/Monitor.

                clozapine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • cyclizine

                cyclizine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • cyclobenzaprine

                cyclobenzaprine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • darifenacin

                darifenacin and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • desipramine

                oxybutynin transdermal and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • dicyclomine

                dicyclomine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • diphenhydramine

                diphenhydramine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • donepezil

                donepezil increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dosulepin

                oxybutynin transdermal and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • doxepin

                oxybutynin transdermal and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • droperidol

                oxybutynin transdermal decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                oxybutynin transdermal decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

                droperidol increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • echothiophate iodide

                echothiophate iodide increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • fesoterodine

                fesoterodine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • finerenone

                oxybutynin transdermal will increase the level or effect of finerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or weak CYP3A4 inhibitors. Adjust finererone dosage as needed.

              • flavoxate

                flavoxate and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • flibanserin

                oxybutynin transdermal will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.

              • fluphenazine

                oxybutynin transdermal decreases levels of fluphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                oxybutynin transdermal decreases levels of fluphenazine by pharmacodynamic antagonism. Use Caution/Monitor.

                fluphenazine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • galantamine

                galantamine increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • glycopyrrolate

                glycopyrrolate and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • glycopyrrolate inhaled

                glycopyrrolate inhaled and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • haloperidol

                oxybutynin transdermal decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                oxybutynin transdermal decreases effects of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor.

                haloperidol increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • henbane

                henbane and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • homatropine

                homatropine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • huperzine A

                huperzine A increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • hyoscyamine

                hyoscyamine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • hyoscyamine spray

                hyoscyamine spray and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • iloperidone

                oxybutynin transdermal decreases levels of iloperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                oxybutynin transdermal decreases levels of iloperidone by pharmacodynamic antagonism. Use Caution/Monitor.

                iloperidone increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • imipramine

                oxybutynin transdermal and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • ipratropium

                ipratropium and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.

              • ivacaftor

                oxybutynin transdermal increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor when coadministered with weak CYP3A4 inhibitors .

              • lemborexant

                oxybutynin transdermal will increase the level or effect of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Lower nightly dose of lemborexant recommended if coadministered with weak CYP3A4 inhibitors. See drug monograph for specific dosage modification.

              • levodopa

                oxybutynin transdermal decreases effects of levodopa by pharmacodynamic antagonism. Use Caution/Monitor.

              • lofepramine

                oxybutynin transdermal and lofepramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • lomitapide

                oxybutynin transdermal increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day.

              • loxapine

                oxybutynin transdermal decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                oxybutynin transdermal decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor.

                loxapine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • loxapine inhaled

                oxybutynin transdermal decreases levels of loxapine inhaled by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                oxybutynin transdermal decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor.

                loxapine inhaled increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • maprotiline

                oxybutynin transdermal and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • meclizine

                meclizine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • methscopolamine

                methscopolamine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • metoclopramide

                oxybutynin transdermal decreases effects of metoclopramide by pharmacodynamic antagonism. Use Caution/Monitor. May antagonize prokinetic effects.

              • midazolam intranasal

                oxybutynin transdermal will increase the level or effect of midazolam intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of mild CYP3A4 inhibitors with midazolam intranasal may cause higher midazolam systemic exposure, which may prolong sedation.

              • neostigmine

                neostigmine increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • nitrofurantoin

                oxybutynin transdermal increases levels of nitrofurantoin by unspecified interaction mechanism. Use Caution/Monitor.

              • nortriptyline

                oxybutynin transdermal and nortriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • olanzapine

                oxybutynin transdermal decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                oxybutynin transdermal decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.

                olanzapine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • onabotulinumtoxinA

                onabotulinumtoxinA and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • orphenadrine

                oxybutynin transdermal and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • oxybutynin

                oxybutynin and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • paliperidone

                oxybutynin transdermal decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                oxybutynin transdermal decreases levels of paliperidone by pharmacodynamic antagonism. Use Caution/Monitor.

                paliperidone increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • pancuronium

                oxybutynin transdermal and pancuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • perphenazine

                oxybutynin transdermal decreases levels of perphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                oxybutynin transdermal decreases levels of perphenazine by pharmacodynamic antagonism. Use Caution/Monitor.

                perphenazine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • physostigmine

                physostigmine increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • pilocarpine

                pilocarpine increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • pilocarpine ophthalmic

                pilocarpine ophthalmic increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • pimozide

                oxybutynin transdermal decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                oxybutynin transdermal decreases levels of pimozide by pharmacodynamic antagonism. Use Caution/Monitor.

                pimozide increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • pralidoxime

                oxybutynin transdermal and pralidoxime both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • prochlorperazine

                oxybutynin transdermal decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                oxybutynin transdermal decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

                prochlorperazine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • promethazine

                oxybutynin transdermal decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                oxybutynin transdermal decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.

                promethazine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • propantheline

                oxybutynin transdermal and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • protriptyline

                oxybutynin transdermal and protriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • pyridostigmine

                pyridostigmine increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • quetiapine

                oxybutynin transdermal decreases levels of quetiapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                oxybutynin transdermal decreases levels of quetiapine by pharmacodynamic antagonism. Use Caution/Monitor.

                quetiapine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • rapacuronium

                oxybutynin transdermal and rapacuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • ribociclib

                ribociclib will increase the level or effect of oxybutynin transdermal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              • rimantadine

                oxybutynin transdermal, rimantadine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Enhanced CNS side effects.

              • risperidone

                oxybutynin transdermal decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                oxybutynin transdermal decreases levels of risperidone by pharmacodynamic antagonism. Use Caution/Monitor.

                risperidone increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • rivastigmine

                rivastigmine increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • rocuronium

                oxybutynin transdermal and rocuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • scopolamine

                oxybutynin transdermal and scopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • solifenacin

                oxybutynin transdermal and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • succinylcholine

                succinylcholine increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • tazemetostat

                oxybutynin transdermal will increase the level or effect of tazemetostat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              • thioridazine

                oxybutynin transdermal decreases levels of thioridazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                oxybutynin transdermal decreases levels of thioridazine by pharmacodynamic antagonism. Use Caution/Monitor.

                thioridazine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • thiothixene

                oxybutynin transdermal decreases levels of thiothixene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                oxybutynin transdermal decreases levels of thiothixene by pharmacodynamic antagonism. Use Caution/Monitor.

                thiothixene increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • tinidazole

                oxybutynin transdermal will increase the level or effect of tinidazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              • tiotropium

                oxybutynin transdermal and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • tolterodine

                oxybutynin transdermal and tolterodine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • trazodone

                oxybutynin transdermal and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • trifluoperazine

                oxybutynin transdermal decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                oxybutynin transdermal decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.

                trifluoperazine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • trihexyphenidyl

                oxybutynin transdermal and trihexyphenidyl both decrease cholinergic effects/transmission. Use Caution/Monitor. Potential for additive anticholinergic effects.

              • trimipramine

                oxybutynin transdermal and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • trospium chloride

                oxybutynin transdermal and trospium chloride both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • vecuronium

                oxybutynin transdermal and vecuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • ziprasidone

                oxybutynin transdermal decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                oxybutynin transdermal decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor.

                ziprasidone increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • zotepine

                oxybutynin transdermal decreases levels of zotepine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                oxybutynin transdermal decreases levels of zotepine by pharmacodynamic antagonism. Use Caution/Monitor.

              Minor (20)

              • acetaminophen

                oxybutynin transdermal decreases levels of acetaminophen by unspecified interaction mechanism. Minor/Significance Unknown.

              • acetaminophen IV

                oxybutynin transdermal decreases levels of acetaminophen IV by unspecified interaction mechanism. Minor/Significance Unknown.

              • acetaminophen rectal

                oxybutynin transdermal decreases levels of acetaminophen rectal by unspecified interaction mechanism. Minor/Significance Unknown.

              • amantadine

                amantadine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Minor/Significance Unknown.

              • atenolol

                atenolol increases levels of oxybutynin transdermal by decreasing metabolism. Minor/Significance Unknown.

              • chlorpromazine

                oxybutynin transdermal increases toxicity of chlorpromazine by unspecified interaction mechanism. Minor/Significance Unknown.

              • digoxin

                oxybutynin transdermal increases levels of digoxin by unspecified interaction mechanism. Minor/Significance Unknown.

              • dimenhydrinate

                dimenhydrinate increases toxicity of oxybutynin transdermal by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • donepezil

                donepezil decreases effects of oxybutynin transdermal by pharmacodynamic antagonism. Minor/Significance Unknown.

              • fluphenazine

                oxybutynin transdermal increases toxicity of fluphenazine by unspecified interaction mechanism. Minor/Significance Unknown.

              • galantamine

                galantamine decreases effects of oxybutynin transdermal by pharmacodynamic antagonism. Minor/Significance Unknown.

              • levodopa

                oxybutynin transdermal, levodopa. Other (see comment). Minor/Significance Unknown. Comment: Anticholinergic agents may enhance the therapeutic effects of levodopa; however, anticholinergic agents can exacerbate tardive dyskinesia. In high dosage, anticholinergics may decrease the effects of levodopa by delaying its GI absorption. .

              • perphenazine

                oxybutynin transdermal increases toxicity of perphenazine by unspecified interaction mechanism. Minor/Significance Unknown.

              • prochlorperazine

                oxybutynin transdermal increases toxicity of prochlorperazine by unspecified interaction mechanism. Minor/Significance Unknown.

              • promazine

                oxybutynin transdermal increases toxicity of promazine by unspecified interaction mechanism. Minor/Significance Unknown.

              • promethazine

                oxybutynin transdermal increases toxicity of promethazine by unspecified interaction mechanism. Minor/Significance Unknown.

              • rimantadine

                rimantadine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Minor/Significance Unknown.

              • ruxolitinib

                oxybutynin transdermal will increase the level or effect of ruxolitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

              • thioridazine

                oxybutynin transdermal increases toxicity of thioridazine by unspecified interaction mechanism. Minor/Significance Unknown.

              • trifluoperazine

                oxybutynin transdermal increases toxicity of trifluoperazine by unspecified interaction mechanism. Minor/Significance Unknown.

              Previous
              Next:

              Adverse Effects

              NOTE: anticholinergic adverse effects are less with transdermal application compared with oral administration

              >10%

              Pruritus at application site (14-16.8%)

              1-10%

              Xerostomia (4.1-9.6%)

              Erythema at application site (5.6-8.3%)

              Constipation (3.3%)

              Vesicles, macules, rash at application site (2.5-3.3%)

              Diarrhea (3.2%)

              Blurred vision (2.5%)

              Dysuria (2.4%)

              Postmarketing Reports

              Nervous system disorders: Memory impairment, dizziness, somnolence, confusion

              Psychiatric disorders: Delirium, hallucinations

              Previous
              Next:

              Warnings

              Contraindications

              Hypersensitivity

              Gastric retention

              Uncontrolled narrow-angle glaucoma

              Urinary retention

              Conditions that severely decrease GI motility

              Cautions

              Caution with clinically significant bladder outflow obstruction because of the risk of urinary retention

              Caution with gastrointestinal obstructive disorders or decreased intestinal motility because of the risk of gastric retention

              Caution with GERD and/or those taking drugs that can cause or exacerbate esophagitis (eg, bisphosphonates)

              Discontinue if skin hypersensitivity occurs

              Avoid use in patients with myasthenia gravis because of decreased cholinergic activity; if experiencing exacerbation of symptoms of myasthenia gravis, oxybutynin-containing product should be discontinued and appropriate therapy promptly provided

              Caution with other anticholinergics (antimuscarinics); may increase risk for xerostomia, constipation, headache, dizziness, somnolence, and blurred vision

              Angioedema requiring hospitalization and emergency medical treatment has occurred with the first or subsequent doses of oral oxybutynin; in the event of angioedema, oxybutynin containing products should be discontinued and appropriate therapy promptly provided

              Previous
              Next:

              Pregnancy & Lactation

              Pregnancy

              There are no studies with topical or oral oxybutynin use in pregnant women to inform a drug associated risk for birth defects or miscarriage; no adverse developmental outcomes observed in animal reproduction studies when administered to pregnant rats and rabbits during organogenesis at approximately 50 and 1 times, respectively, the maximum human dose based on body surface area

              Lactation

              There is no information on presence of drug in human milk, effects on breastfed child, or on milk production; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from therapy or from the underlying maternal condition

              Pregnancy Categories

              A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

              B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

              C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

              D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

              X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

              NA: Information not available.

              Previous
              Next:

              Pharmacology

              Mechanism of Action

              Exerts antispasmodic and antimuscarinic effects on smooth muscle; decreases uninhibited contractions, and delays desire to void; increases bladder capacity

              Pharmacokinetics

              Peak Plasma Concentration: 3-6.6 ng/mL

              Metabolism: bypasses first-pass in liver by CYP3A4, AUC ratio of N-desethyloxybutynin (active metabolite) to parent compound is 1:1

              Previous
              Next:

              Images

              BRAND FORM. UNIT PRICE PILL IMAGE
              Oxytrol transdermal
              -
              3.9 mg/24 hr transdermal system
              Oxytrol transdermal
              -
              3.9 mg/24 hr transdermal system
              Oxytrol transdermal
              -
              3.9 mg/24 hr transdermal system
              Oxytrol transdermal
              -
              3.9 mg/24 hr transdermal system
              Gelnique transdermal
              -
              100 mg/gram (10 %) gel
              Gelnique transdermal
              -
              10 % (100 mg/gram) gel
              Gelnique transdermal
              -
              10 % (100 mg/gram) gel
              Oxytrol For Women transdermal
              -
              3.9 mg/24 hour transdermal system
              Oxytrol For Women transdermal
              -
              3.9 mg/24 hour transdermal system

              Copyright © 2010 First DataBank, Inc.

              Previous
              Next:

              Patient Handout

              Patient Education
              oxybutynin transdermal

              OXYBUTYNIN GEL PUMP - TRANSDERMAL

              (OX-i-BUE-ti-nin)

              COMMON BRAND NAME(S): Gelnique

              USES: This medication is used to treat an overactive bladder. Oxybutynin improves your ability to control your urination by relaxing the muscles in the bladder. It helps to reduce leaking of urine, feelings of needing to urinate right away, and frequent trips to the bathroom. This medication belongs to the class of drugs known as antispasmodics.

              HOW TO USE: Read the Patient Information Leaflet provided by your pharmacist before you start using oxybutynin and each time you get a refill. If you have any questions, ask your doctor or pharmacist.Using mild soap and water, wash your hands and the area of skin where the gel will be applied. Allow the area to dry completely before applying.Prime the pump before using for the first time as directed by the Patient Information Leaflet.Apply the gel to an area of skin on the shoulders/upper arms, abdomen, or thigh as directed by your doctor, usually once daily. Do not apply to the breasts or groin. Do not apply the gel to open sores, scars, tattoos, areas with a rash, recently shaved, irritated, or oily skin. Gently rub into your skin until it dries. Do not continue rubbing after the gel has dried. This medication may be used before or after applying sunscreen.Oxybutynin gel is for use on the skin only. Avoid getting the gel in the eyes, nose, or mouth. Wash your hands with soap and water after applying this medication. If the gel gets in your eyes, rinse your eyes right away with warm, clean water.You may apply the gel to a different area of skin with each dose to reduce the chances of having skin reactions at the application site.Allow this medication to dry completely on the skin before getting dressed. Cover the area to prevent spreading the medication through skin contact. If contact occurs, immediately wash the area with soap and water. After applying the gel, wait 1 hour before exercising, bathing, showering, swimming, or getting the application area wet, to make sure all the drug is absorbed. This medication contains alcohol. Avoid smoking and open flame until the gel has dried.Use this medication regularly in order to get the most benefit from it. To help you remember, use it at the same time each day.Tell your doctor if your condition persists or worsens.

              SIDE EFFECTS: Skin redness/itching/swelling at the application site, dry mouth, constipation, dizziness, drowsiness, or blurred vision may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.To relieve dry mouth, suck (sugarless) hard candy or ice chips, chew (sugarless) gum, drink water or use a saliva substitute.To prevent constipation, eat dietary fiber, drink enough water, and exercise. You may also need to take a laxative. Ask your pharmacist which type of laxative is right for you.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor right away if you have any serious side effects, including: difficulty urinating, signs of kidney infection (such as burning/painful/frequent urination, lower back pain), mental/mood changes (such as confusion, hallucinations), signs of stomach/intestinal blockage (such as severe stomach pain, persistent nausea/vomiting, severe constipation).A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

              PRECAUTIONS: Before using oxybutynin, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: blockage/slowed movement of the stomach/intestines (such as severe constipation, gastric retention, paralytic ileus), stomach/intestinal disease (such as acid reflux, hiatal hernia, ulcerative colitis), problems emptying your bladder (such as urinary retention, obstruction, enlarged prostate), a certain eye problem (glaucoma), liver disease, kidney disease, a certain muscle disease (myasthenia gravis), Parkinson's disease, a certain nervous system disorder (autonomic neuropathy).This drug may make you dizzy or drowsy or blur your vision. Alcohol or marijuana (cannabis) can make you more dizzy or drowsy. Do not drive, use machinery, or do anything that needs alertness or clear vision until you can do it safely. Limit alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).This medication may make you sweat less, making you more likely to get heat stroke. Avoid doing things that may cause you to overheat, such as hard work or exercise in hot weather, or using hot tubs. When the weather is hot, drink a lot of fluids and dress lightly. If you overheat, quickly look for a place to cool down and rest. Get medical help right away if you have a fever that does not go away, mental/mood changes, headache, or dizziness.Older adults may be more sensitive to the side effects of this drug, especially drowsiness, confusion, constipation, trouble urinating. Drowsiness and confusion can increase the risk of falling.During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.It is unknown if this drug passes into breast milk. Consult your doctor before breast-feeding.

              DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug include: pramlintide, drugs that can irritate the esophagus/stomach (such as potassium tablets/capsules, oral bisphosphonates including alendronate, etidronate), drugs that can cause dry mouth and constipation (including anticholinergic medications such as atropine/scopolamine, antihistamines such as diphenhydramine, other antispasmodics including dicyclomine, belladonna alkaloids)..Tell your doctor or pharmacist if you are using other products that cause drowsiness such as opioid pain or cough relievers (such as codeine, hydrocodone), alcohol, marijuana (cannabis), drugs for sleep or anxiety (such as alprazolam, lorazepam, zolpidem), muscle relaxants (such as carisoprodol, cyclobenzaprine), or antihistamines (such as cetirizine, diphenhydramine).Check the labels on all your medicines (such as allergy or cough-and-cold products) because they may contain ingredients that can cause drowsiness, constipation or blurred vision. Ask your pharmacist about using those products safely.

              OVERDOSE: This medicine may be harmful if swallowed. If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include unusual excitement, agitation, fast/irregular heartbeat, hot/flushed skin, fever.

              NOTES: Do not share this medication with others.

              MISSED DOSE: If you miss a dose, use it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Use your next dose at the regular time. Do not double the dose to catch up.

              STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom or near an open flame. This medication is flammable. Avoid smoking and open flame until the gel has dried. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.

              Information last revised August 2021. Copyright(c) 2021 First Databank, Inc.

              IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

              Previous
              Next:

              Formulary

              FormularyPatient Discounts

              Adding plans allows you to compare formulary status to other drugs in the same class.

              To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

              Adding plans allows you to:

              • View the formulary and any restrictions for each plan.
              • Manage and view all your plans together – even plans in different states.
              • Compare formulary status to other drugs in the same class.
              • Access your plan list on any device – mobile or desktop.

              The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

              Tier Description
              1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
              2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
              3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
              4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              NC NOT COVERED – Drugs that are not covered by the plan.
              Code Definition
              PA Prior Authorization
              Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
              QL Quantity Limits
              Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
              ST Step Therapy
              Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
              OR Other Restrictions
              Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
              Additional Offers
              Email to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Email Forms to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Previous
              Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.